You are here

Article Text

Article menu
Download PDFPDF
Featured editorial
More about the “ARB MI paradox”
  1. Alistair S Hall1,
  2. Martin H Strauss2
  1. 1C-NET Research Group, LIGHT (Leeds Institute for Genetics Health and Therapeutics), Faculty of Medicine, University of Leeds, UK
  2. 2Division of Cardiovascular Surgery, Saint Michael’s Hospital and Division of Cardiology, North York General Hospital, Toronto, Canada
  1. Correspondence to:
    Professor A S Hall
    C-NET Research Group, G Floor, Jubilee Wing, Great George Street, Leeds LS1 3EX, UK; a.s.hall{at}leeds.ac.uk

Abstract

“Logic dictates that angiotensin converting enzyme inhibitors should remain the preferred drug across the entire spectrum of cardiometabolic disease”

  • ACEi, angiotensin converting enzyme inhibitors
  • ARB, angiotensin receptor blocker
  • CV, cardiovascular
  • MI, myocardial infarction
  • angiotensin
  • antagonist
  • infarction
  • myocardial
  • receptor

https://doi.org/10.1136/hrt.2006.107185

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Conflict of interest: Professor Hall has received research grants from Astra-Zeneca, Servier UK, and Sanofi-Aventis UK; has received honoraria from Astra-Zeneca and Servier UK; and has been paid consultant fees by Servier UK. Dr Strauss has received honoraria from Sanofi-Aventis, Pfizer, Abbott, and Tanabe; has served as an expert witness for Sanofi-Aventis; and has served as a consultant/advisory board member for Sanofi-Aventis and Pfizer.